ILD SEVERITY AND CLINICAL MANAGEMENT IN THE REAL-WORLD SETTING
Author(s)
Amanda G. Althoff, MS1, Lawrence Rasouliyan, MPH2, Danae Black, MPH, PhD3;
1OMNY Health, Senior Data Scientist, Atlanta, GA, USA, 2OMNY Health, Alpharetta, GA, USA, 3OMNY Health, Washington, DC, USA
1OMNY Health, Senior Data Scientist, Atlanta, GA, USA, 2OMNY Health, Alpharetta, GA, USA, 3OMNY Health, Washington, DC, USA
Presentation Documents
OBJECTIVES: To characterize patients with interstitial lung disease (ILD) and their treatment management by severity in the real-world setting.
METHODS: This retrospective study used electronic health records (2017-2025) from the OMNY Health real-world data platform. Patients with an ILD diagnosis (ICD-10-CM: J84*) were selected if they had a forced vital capacity (FVC) percent predicted measurement on or after their first observed ILD diagnosis (index FVC), which was used to determine severity (mild: ≥ 70%, moderate: ≥ 60% and < 70%, moderately severe: ≥ 50% and < 60%, severe: ≥ 35% and < 50%, very severe: < 35%). Proportion of patients by severity was tabulated for common comorbidities on or prior to the index FVC and for common treatments at the same visit as the index FVC.
RESULTS: Among approximately 375,000 patients with an ILD diagnosis, 27,802 patients were included in this study. Patients were classified into mild (61%), moderate (16%), moderately severe (12%), severe (9%), and very severe (3%). The proportion of male and nonwhite patients increased (45% to 50% and 14% to 23%, respectively) while the median age decreased (71 to 67 years) with severity. Top comorbidities across severity groups were gastro-esophageal reflux disease (34/30/28/25/31%), anxiety or depression (28/25/24/23/25%), obstructive sleep apnea (23/24/23/22/21%), coronary artery disease (23/23/22/20/20%), and diabetes (21/26/26/24/24%). Oral corticosteroid and antifibrotic/cytotoxic drug use increased monotonically with worsening severity (7%-22% and 2%-8%, respectively). Biologics, pulmonary rehabilitation, and lung transplant surgery were all used on less than 1% of patients.
CONCLUSIONS: Worsening ILD severity based on FVC percent predicted was associated with an increased use in oral corticosteroids and antifibrotic/cytotoxic drugs. Further analyses looking at treatment patterns in relation to change in severity over time would be beneficial to better understand how differing severity influences treatment management for ILD patients.
METHODS: This retrospective study used electronic health records (2017-2025) from the OMNY Health real-world data platform. Patients with an ILD diagnosis (ICD-10-CM: J84*) were selected if they had a forced vital capacity (FVC) percent predicted measurement on or after their first observed ILD diagnosis (index FVC), which was used to determine severity (mild: ≥ 70%, moderate: ≥ 60% and < 70%, moderately severe: ≥ 50% and < 60%, severe: ≥ 35% and < 50%, very severe: < 35%). Proportion of patients by severity was tabulated for common comorbidities on or prior to the index FVC and for common treatments at the same visit as the index FVC.
RESULTS: Among approximately 375,000 patients with an ILD diagnosis, 27,802 patients were included in this study. Patients were classified into mild (61%), moderate (16%), moderately severe (12%), severe (9%), and very severe (3%). The proportion of male and nonwhite patients increased (45% to 50% and 14% to 23%, respectively) while the median age decreased (71 to 67 years) with severity. Top comorbidities across severity groups were gastro-esophageal reflux disease (34/30/28/25/31%), anxiety or depression (28/25/24/23/25%), obstructive sleep apnea (23/24/23/22/21%), coronary artery disease (23/23/22/20/20%), and diabetes (21/26/26/24/24%). Oral corticosteroid and antifibrotic/cytotoxic drug use increased monotonically with worsening severity (7%-22% and 2%-8%, respectively). Biologics, pulmonary rehabilitation, and lung transplant surgery were all used on less than 1% of patients.
CONCLUSIONS: Worsening ILD severity based on FVC percent predicted was associated with an increased use in oral corticosteroids and antifibrotic/cytotoxic drugs. Further analyses looking at treatment patterns in relation to change in severity over time would be beneficial to better understand how differing severity influences treatment management for ILD patients.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HSD45
Topic
Health Service Delivery & Process of Care
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)